Trideum Biosciences Announces Antimicrobial Efficacy of a Novel Cold Plasma Technology Developed by ChiScan
Huntsville, AL (PRWEB) May 06, 2016
Trideum Biosciences revealed the results of their antimicrobial efficacy testing of ChiScan Cold Plasma technology. “Our laboratory has been conducting efficacy testing of this novel next-generation cold plasma technology and I am pleased to announce our testing results demonstrated effectiveness against all the bacterial and fungal pathogens tested” said Dr. Mina Izadjoo, VP and Chief Science Officer of Trideum Biosciences. She also added “We have selected Dr. Hosan Kim, who has extensive experience in antimicrobial efficacy evaluation, to conduct the ongoing testing. The results of antimicrobial testing have been presented in a number of scientific conferences and will be published in peer reviewed journals. This revolutionary cold plasma technology is a promising antibacterial and antifungal medical device for treating localized bacterial and dermatophytic infections and can be used as a countermeasure for multidrug-resistant and hard-to-treat infectious agents.”
TEMPE, Ariz., March 28, 2016 — Fast-growing Huntsville company Trideum is teaming with Tempe, Arizona company ChiScan to further develop what the two are calling next-generation technology.
Trideum Biosciences and ChiScan have signed a memorandum of understanding for the testing and development of a novel cold plasma technology. There has been increased research in this technology for its use in preventing food contamination and bacterial growth.
“We are excited about entering this strategic agreement and partnership with Trideum Biosciences, where antimicrobial efficacy testing of our technology under the scientific leadership of (Trideum chief scientific officer) Dr. Mina Izadjoo is underway,” says ChiScan CEO Huan Truong.
ChiScan Signs Agreement with Trideum Biosciences to Collaborate on Testing and Advancing a Next-Generation Smart Cold Plasma Technology
TEMPE, Ariz., March 24, 2016 /PRNewswire/ — ChiScan LLC and Trideum Biosciences LLC announce signing of a Memorandum of Understanding (MOU) for testing and development of a novel cold plasma technology.
“We are very pleased to have entered into this agreement with ChiScan. This agreement continues to build on a working relationship between our teams,” Van Sullivan, President and CEO of Trideum Biosciences said.
Huan Truong, CEO of ChiScan said, “We are excited about entering this strategic agreement and partnership with Trideum Biosciences, where antimicrobial efficacy testing of our technology under the scientific leadership of Dr. Mina Izadjoo is underway.” He also mentioned that ChiScan’s expertise is on design of this unique Cold Plasma technology and our collaborative relationship with Trideum Biosciences helps us provide the laboratory testing and scientific evidence on the efficacy of our products.
Van Sullivan said “This agreement enhances our ongoing and future collaboration. We value this partnership and are excited to be part of development of this novel Next Generation cold plasma technology.”
Next generation Non-Thermal Plasma Technology demonstrates effectiveness in the fight against tough infectious agents
TEMPE, Ariz., Jan. 7, 2016 /PRNewswire/ — ChiScan is pleased to announce development of a novel device for creating Non-Thermal Plasma (NTP). Huan Truong (ChiScan CEO) stated that, “Although there are currently a number of technologies capable of generating cold plasma, our proprietary cold plasma generating technology is novel due to its size, portability, no requirement for any noble gas, precision, robustness, and its ease of application.” ChiScan technology has significant utility as a countermeasure for multidrug-resistant and hard-to-treat infectious agents in both clinical and field settings. This next generation cold plasma technology is the result of more than ten years of research and development.